UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Peripheral nerve tumors

Authors
James M Gilchrist, MD
John E Donahue, MD
Section Editors
Jeremy M Shefner, MD, PhD
Robert Maki, MD, PhD
Deputy Editor
April F Eichler, MD, MPH

INTRODUCTION

Peripheral nerve tumors are uncommon and many neurologists will see only a handful in their careers, unless they have a practice enriched in patients with neurofibromatosis.

This topic review will focus on various benign and malignant neoplasms and benign non-neoplastic tumors of the peripheral nerve. The neurofibromatoses are discussed separately. (See "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis" and "Neurofibromatosis type 2" and "Schwannomatosis".)

Nerve sheath tumors affecting the spinal cord are reviewed elsewhere. (See "Intradural nerve sheath tumors".)

CLINICAL PRESENTATION

Symptoms and signs of peripheral nerve tumors are caused by direct nerve invasion, involvement of surrounding tissues, or mass effect [1]. There are no specific clinical presentations unique or even especially suggestive of a particular nerve tumor, with the exception of neurofibromatosis type 1 and neurofibromatosis type 2. (See "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis" and "Neurofibromatosis type 2".)

Patients present for evaluation of peripheral nerve tumors because of a soft tissue mass, pain, or focal neurologic findings, approximately in that order of frequency [2]. The duration and progression of symptoms or signs is important as most benign tumors have a longer duration and a slow rate of progression, while malignant tumors tend to progress rapidly in size, amount of pain, and neurologic deficit [2-4]. Any mass changing its clinical character should be taken seriously, as that is one of the few clinical clues to its potentially malignant nature. In particular, rapidly expanding soft tissue masses are very suspicious for the presence of a malignant peripheral nerve sheath tumor and should be evaluated promptly [3]. A careful family history is important in the assessment of an underlying neurogenetic disorder, such as neurofibromatosis.

                                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Nov 15 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Mrugala MM, Batchelor TT, Plotkin SR. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol 2005; 18:604.
  2. Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology 2003; 61:696.
  3. Valeyrie-Allanore L, Ismaïli N, Bastuji-Garin S, et al. Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1. Br J Dermatol 2005; 153:79.
  4. Perrin RG, Guha A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am 2004; 15:203.
  5. Donner TR, Voorhies RM, Kline DG. Neural sheath tumors of major nerves. J Neurosurg 1994; 81:362.
  6. Bhattacharyya AK, Perrin R, Guha A. Peripheral nerve tumors: management strategies and molecular insights. J Neurooncol 2004; 69:335.
  7. Pilavaki M, Chourmouzi D, Kiziridou A, et al. Imaging of peripheral nerve sheath tumors with pathologic correlation: pictorial review. Eur J Radiol 2004; 52:229.
  8. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002; 62:1573.
  9. Golan JD, Jacques L. Nonneoplastic peripheral nerve tumors. Neurosurg Clin N Am 2004; 15:223.
  10. Brooks DG. The neurofibromatoses: hereditary predisposition to multiple peripheral nerve tumors. Neurosurg Clin N Am 2004; 15:145.
  11. Tiel R, Kline D. Peripheral nerve tumors: surgical principles, approaches, and techniques. Neurosurg Clin N Am 2004; 15:167.
  12. Bourke G, Owen J, Machet D. Histological comparison of the third interdigital nerve in patients with Morton's metatarsalgia and control patients. Aust N Z J Surg 1994; 64:421.
  13. Wu KK. Morton's interdigital neuroma: a clinical review of its etiology, treatment, and results. J Foot Ankle Surg 1996; 35:112.
  14. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995; 267:381.
  15. Kim DH, Murovic JA, Tiel RL, et al. A series of 146 peripheral non-neural sheath nerve tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg 2005; 102:256.
  16. George DH, Scheithauer BW, Spinner RJ, et al. Heterotopic ossification of peripheral nerve ("neuritis ossificans"): report of two cases. Neurosurgery 2002; 51:244.
  17. Pérez-López C, Gutiérrez M, Isla A. Inflammatory pseudotumor of the median nerve. Case report and review of the literature. J Neurosurg 2001; 95:124.
  18. Koszyca B, Jones N, Kneebone C, Blumbergs P. Localized hypertrophic neuropathy: a case report and review of the literature. Clin Neuropathol 2009; 28:54.
  19. Stumpo M, Foschini MP, Poppi M, et al. Hypertrophic inflammatory neuropathy involving bilateral brachial plexus. Surg Neurol 1999; 52:458.
  20. Maher CO, Spinner RJ, Giannini C, et al. Neuromuscular choristoma of the sciatic nerve. Case report. J Neurosurg 2002; 96:1123.
  21. Ferraresi S, Garozzo D, Bianchini E. Aggressive fibromatosis (desmoid tumor) of the radial nerve: favorable resolution. Case report. J Neurosurg 2001; 95:332.
  22. Fetsch JF, Laskin WB, Miettinen M. Nerve sheath myxoma: a clinicopathologic and immunohistochemical analysis of 57 morphologically distinctive, S-100 protein- and GFAP-positive, myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate. Am J Surg Pathol 2005; 29:1615.
  23. Harkin, JC, Reed, RJ. Solitary benign nerve sheath tumors. In: Atlas of Tumor Pathology: Tumors of the Peripheral Nervous System, 2, Firminger, HI (Eds), Armed Forces Institute of Pathology, Washington, DC 1959. p.60.
  24. Gallager RL, Helwig EB. Neurothekeoma--a benign cutaneous tumor of neural origin. Am J Clin Pathol 1980; 74:759.
  25. Busam KJ, Mentzel T, Colpaert C, et al. Atypical or worrisome features in cellular neurothekeoma: a study of 10 cases. Am J Surg Pathol 1998; 22:1067.
  26. Laskin WB, Fetsch JF, Miettinen M. The "neurothekeoma": immunohistochemical analysis distinguishes the true nerve sheath myxoma from its mimics. Hum Pathol 2000; 31:1230.
  27. Hornick JL, Fletcher CD. Cellular neurothekeoma: detailed characterization in a series of 133 cases. Am J Surg Pathol 2007; 31:329.
  28. Stratton J, Billings SD. Cellular neurothekeoma: analysis of 37 cases emphasizing atypical histologic features. Mod Pathol 2014; 27:701.
  29. Chang, SD, Kim, DH, Hudson, AR, Kline, DG. Peripheral Nerve Tumors. In: Neuromuscular Disorders in Clinical Practice, Katirji, B, Kaminski, HJ, Preston, DC, et al (Eds), Butterworth-Heinemann, Boston 2002. p.828.
  30. Skovronsky DM, Oberholtzer JC. Pathologic classification of peripheral nerve tumors. Neurosurg Clin N Am 2004; 15:157.
  31. Kim DH, Murovic JA, Tiel RL, Kline DG. Operative outcomes of 546 Louisiana State University Health Sciences Center peripheral nerve tumors. Neurosurg Clin N Am 2004; 15:177.
  32. Hirose T, Scheithauer BW, Sano T. Perineurial malignant peripheral nerve sheath tumor (MPNST): a clinicopathologic, immunohistochemical, and ultrastructural study of seven cases. Am J Surg Pathol 1998; 22:1368.
  33. MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64:1838.
  34. El-Sherif Y, Sarva H, Valsamis H. Clinical reasoning: an unusual lung mass causing focal weakness. Neurology 2012; 78:e4.
  35. Rankine AJ, Filion PR, Platten MA, Spagnolo DV. Perineurioma: a clinicopathological study of eight cases. Pathology 2004; 36:309.
  36. Tsang WY, Chan JK, Chow LT, Tse CC. Perineurioma: an uncommon soft tissue neoplasm distinct from localized hypertrophic neuropathy and neurofibroma. Am J Surg Pathol 1992; 16:756.
  37. Giannini C, Scheithauer BW, Jenkins RB, et al. Soft-tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature. Am J Surg Pathol 1997; 21:164.
  38. Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology 2014; 46:95.
  39. Harder A, Wesemann M, Hagel C, et al. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am J Surg Pathol 2012; 36:702.
  40. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World Health Organization Classification of tumours of soft tissue and bone, 4th, IARC Press, Lyon 2013.
  41. Lee D, Suh YL, Han J, Kim ES. Spinal nerve sheath myxoma (neurothekeoma). Pathol Int 2006; 56:144.
  42. Modha A, Paty P, Bilsky MH. Presacral ganglioneuromas. Report of five cases and review of the literature. J Neurosurg Spine 2005; 2:366.
  43. Escott EJ, Kleinschmidt-DeMasters BK, Brega K, Lillehei KO. Proximal nerve root spinal hemangioblastomas: presentation of three cases, MR appearance, and literature review. Surg Neurol 2004; 61:262.
  44. Kim DH, Murovic JA, Tiel RL, et al. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg 2005; 102:246.
  45. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006.
  46. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39:311.
  47. Tucker T, Wolkenstein P, Revuz J, et al. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005; 65:205.
  48. Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol 2012; 19:878.
  49. Patel TD, Shaigany K, Fang CH, et al. Comparative Analysis of Head and Neck and Non-Head and Neck Malignant Peripheral Nerve Sheath Tumors. Otolaryngol Head Neck Surg 2016; 154:113.
  50. Brahmi M, Thiesse P, Ranchere D, et al. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients. PLoS One 2015; 10:e0138386.
  51. Stasik CJ, Tawfik O. Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch Pathol Lab Med 2006; 130:1878.
  52. McConnell YJ, Giacomantonio CA. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival. J Surg Oncol 2012; 106:51.
  53. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 1999; 155:1879.
  54. Zhou H, Coffin CM, Perkins SL, et al. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol 2003; 27:1337.
  55. Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 2014; 46:1227.
  56. Zhang M, Wang Y, Jones S, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet 2014; 46:1170.
  57. Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2013; 123:340.
  58. Hirbe AC, Pekmezci M, Dahiya S, et al. BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro Oncol 2014; 16:466.
  59. Serrano C, Simonetti S, Hernández-Losa J, et al. BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours. Histopathology 2013; 62:499.
  60. Porter DE, Prasad V, Foster L, et al. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma 2009; 2009:756395.
  61. Levi AD, Ross AL, Cuartas E, et al. The surgical management of symptomatic peripheral nerve sheath tumors. Neurosurgery 2010; 66:833.
  62. Kolberg M, Høland M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol 2013; 15:135.
  63. Amirian ES, Goodman JC, New P, Scheurer ME. Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program. J Neurooncol 2014; 116:609.
  64. Hagel C, Zils U, Peiper M, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol 2007; 82:187.
  65. Ramchandren S, Dalmau J. Metastases to the peripheral nervous system. J Neurooncol 2005; 75:101.
  66. Jaeckle KA, Young DF, Foley KM. The natural history of lumbosacral plexopathy in cancer. Neurology 1985; 35:8.
  67. Grisold W, Piza-Katzer H, Jahn R, Herczeg E. Intraneural nerve metastasis with multiple mononeuropathies. J Peripher Nerv Syst 2000; 5:163.
  68. Chang PC, Fischbein NJ, McCalmont TH, et al. Perineural spread of malignant melanoma of the head and neck: clinical and imaging features. AJNR Am J Neuroradiol 2004; 25:5.
  69. Levin N, Soffer D, Grissaru S, et al. Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis. J Neurooncol 2008; 90:77.
  70. Bezier M, Reguiaï Z, Delaby P, et al. Neurolymphomatosis associated with Sézary syndrome. Arch Dermatol 2009; 145:294.